Efficacy and safety of veliparib combined with traditional chemotherapy for treating patients with lung cancer: a comprehensive review and meta-analysis

• Published in: PeerJ (San Francisco, CA) CA), 2023-11, Vol.11, p.e16402-e16402, Article e16402
• Main Authors: Zhao, Guanhua, Feng, Enzhi, Liu, Yalu
• Format: Article
• Language: English
• Subjects: Adenosine diphosphate; Analysis; Anemia; Apoptosis; Bias; Breast cancer; Cancer; Cancer patients; Cancer therapies; Cell death; Cell survival; Chemotherapy; Clinical trials; Development and progression; DNA damage; DNA repair; Drug therapy; Drugs and Devices; Enzymes; Evidence-based medicine; Genes; Handbooks; Health aspects; Intervention; Leukopenia; Lung Cancer; Lung cancer, Non-small cell; Medical research; Meta-analysis; Mutation; Neutropenia; Non-small cell lung carcinoma; Oncology; PARP Inhibitor; Patients; Proteins; Radiation therapy; Registration; Respiratory agents; Respiratory Medicine; Small cell lung carcinoma; Statistical analysis; Systematic review; Thrombocytopenia; Veliparib
• ISSN: 2167-8359; 2167-8359
• DOI: 10.7717/peerj.16402

Objective Lung cancer, originating from bronchial mucosa or lung glands, poses significant health risks due to its rising incidence and mortality. This study aimed to assess the efficacy and safety of Veliparib combined with chemotherapy versus pharmacotherapy alone for lung cancer treatment, guiding clinical approaches for this severe disease. Methods Comprehensive searches in PubMed, EMBASE, Cochrane, and Web of Science were conducted to identify randomized controlled trials (RCTs) comparing Veliparib combined with standard chemotherapy to chemotherapy alone in lung cancer treatment, up until December 28, 2022. Two reviewers meticulously selected literature based on inclusion and exclusion criteria. The Cochrane tool was used to assess the bias risk of the included studies, and meta-analysis was performed using Stata 15.0. Results Five RCTs (1,010 participants) were included. The analysis results showed that only Veliparib combinedwith chemotherapy prolonged the progression-free survival (PFS) in small cell lung cancer (SCLC) patients [HR = 0.72, 95% CI = (0.57, 0.90)]. No significant differences were observed in overall survival (OS) and objective response rate (ORR). Veliparib and combined chemotherapy caused some side effects in patients with lung cancer, including leukopenia [RR = 2.12, 95% CI = (1.27, 3.55)], neutropenia [RR = 1.51, 95% CI = (1.01, 2.26)], anemia [RR = 1.71, 95% CI = (1.07, 3.07)], and thrombocytopenia [RR = 3.33, 95% CI = (1.19, 9.30)]. For non-small cell lung cancer (NSCLC) patients, there were no statistically significant differences in PFS, OS, or ORR between the experimental and control groups [HR = 0.97, 95% CI = (0.75, 1.27)]. Conclusion The strategy of combining Veliparib with chemotherapy may, to some extent, prolong the PFS in lung cancer patients. However, this benefit is not observed in OS or ORR. Additionally, there are evident adverse reactions. Due to a limited number of the included studies, additional extensive multicenter RCTs are required to validate these results. PROSPERO registration number: CRD42023411510.